Lisa Anson, Redx Pharma CEO

With PhII fail, Redx Phar­ma scraps monother­a­py bil­iary can­cer de­vel­op­ment for lead pro­gram

UK biotech Redx Phar­ma’s lead drug has failed a Phase II study for bil­iary tract can­cer, and the re­sults are “not suf­fi­cient” to con­tin­ue de­vel­op­ment as a monother­a­py in that in­di­ca­tion, the com­pa­ny an­nounced Wednes­day.

RXC004, a por­cu­pine in­hibitor be­ing de­vel­oped to treat Wnt-lig­and de­pen­dent can­cers in pa­tients whose dis­ease pro­gressed af­ter oth­er treat­ments, failed to hit the pri­ma­ry end­point — pro­gres­sion-free sur­vival at six months.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.